Pharmacokinetics of muzolimine after acute and chronic dosing in hypertensive patients with mild renal insufficiency.

Abstract

Pharmacokinetics and clinical effects of muzolimine were investigated in 6 hypertensive patients with incipient renal insufficiency. Muzolimine plasma levels were determined after the first dose and after 8 weeks of treatment with muzolimine (20 mg o.d.). The area under the curve of muzolimine plasma levels was greater after 8 weeks than after the first dose. Also, peak plasma concentrations were higher after 8 weeks; however, muzolimine half-lives in the beta-phase were unchanged. Blood pressure and body weight decreased with time. Muzolimine was well tolerated.

• Authors: J Mann, W Ritter, N Heckmann, F Sörgel, E Ritz
• Journal: Zeitschrift fur Kardiologie (Z Kardiol) Vol. 74 Suppl 2 Pg. 77-9 ( 1985) ISSN: 0300-5860 [Print] Germany
• PMID: 4002808 (Publication Type: Journal Article)

Chemical References

• Pyrazoles
• Muzolimine
• Creatinine

Topics

• Adult
• Blood Pressure (drug effects)
• Creatinine (urine)
• Humans
• Hypertension (complications, drug therapy, physiopathology)
• Kidney Diseases (complications)
• Kinetics
• Middle Aged
• Muzolimine (blood, therapeutic use)
• Pyrazoles (blood)
• Time Factors